Spotlight session: In-vivo CAR-T: The next frontier in cell therapy

Traditional ex vivo CAR-T therapies face challenges in manufacturing complexity, scalability, and patient accessibility. In vivo engineering offers the possibility of streamlined production and broader application across indications. This session explores scientific, translational, and regulatory considerations for advancing in vivo CAR-T as the next stage in cell therapy innovation. 

Key takeaways: 

• Compare in vivo and ex vivo CAR-T approaches with respect to scalability and patient access. 

• Examine safety margins and dosing strategies for in vivo CAR-T platforms. 

• Assess translational fidelity and predictive validity in preclinical models of in vivo CAR-T. 

• Explore delivery modalities and vector systems for efficient in vivo T cell engineering. 

• Consider regulatory perspectives and clinical trial design challenges for in vivo CAR-T development.